UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000006804 |
|---|---|
| Receipt number | R000008053 |
| Scientific Title | PhaseII trial of capecitabine plus cisplatin in patients with recurrent HER-2 negative gastric cancer during or after the adjuvant chemotherapy using S-1 (T-CORE1102) |
| Date of disclosure of the study information | 2011/12/01 |
| Last modified on | 2020/07/07 15:39:28 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2011/11/30 19:30:39 | ||
| 2 | Update | 2011/11/30 19:32:29 | Public title Acronym |
|
| 3 | Update | 2012/01/04 20:36:27 | Recruitment status |
|
| 4 | Update | 2014/12/01 12:14:26 | Interventions/Control_1 |
|
| 5 | Update | 2014/12/01 12:15:47 | Email |
|
| 6 | Update | 2015/06/01 15:10:58 | Last name of contact person Last name of contact person |
|
| 7 | Update | 2016/01/05 09:23:53 | Email |
|
| 8 | Update | 2017/06/05 08:47:10 | Recruitment status |
|
| 9 | Update | 2018/06/05 10:53:09 | Last name of contact person Last name of contact person Name of person sending information Name of primary person or sponsor Institute Organization Organization |
|
| 10 | Update | 2019/02/18 13:54:21 | Last name of lead principal investigator Last name of lead principal investigator Organization Organization Division name Division name Address Address TEL Organization1 Address1 Tel1 Email1 |
|
| 11 | Update | 2020/07/07 15:35:02 | Date of IRB |
|
| 12 | Update | 2020/07/07 15:35:26 | Recruitment status |
|
| 13 | Update | 2020/07/07 15:36:59 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Last name of contact person Last name of contact person Zip code Organization Organization Address Address Tel |
|
| 14 | Update | 2020/07/07 15:39:06 | Last follow-up date |
|
| 15 | Update | 2020/07/07 15:39:28 | Number of participants that the trial has enrolled |
